Outsourcing

A RoTab tablet press can product up to 42,000 tablets per hour for Juniper Pharma Services.

Recipharm adds hardware, software, and cloud services for serialization compliance processes.

Brammer Bio establishes late-phase development and commercial manufacturing facility for advanced cell and gene therapies in Lexington, MA.

The new company is the product of a merger with Formex.

Uncertainty about the demand for a biologic medication can be partly mollified with some well-planned capacity outsourcing, contends a new report by ORC International sponsored by Patheon.

Industry experts discuss common considerations and recent technological advancements in blow-fill-seal technology.

Process analytical technology paved the way for continuous manufacturing.

Acquisition binges often lead to hangovers; here’s what to watch out for.

The company expanded its topicals capacity with an investment in the Becomix RW30 model homogenizer.

PharmTech sat down with an intellectual property lawyer to examine how companies are protected when they engage in activities where sharing of trade secrets must occur.

Investment at SGS’s Mississauga, Canada facility provides for analysis of molecular interactions in real time.

Growth may be slowing, but outsourcing activity remains healthy.

Siegfried Schmitt, Principal Consultant, PAREXEL International, discusses how to report quality metrics to FDA.

With deadlines only a few years away, some companies have not started serialization programs, while others are taking a tactical, short-term approach, losing out on potential business benefits.

MilliporeSigma, the North American life-sciences business of Germany’s Merck KGaA, added a 2000-L single-use bioreactor to its facility in Massachusetts.

WellSpring Pharma formed a strategic partnership with IDT Australia and invested $3 million in new equipment.

A program for calibration and routine testing of weighing instruments ensures accurate results.

Transferring the manufacturing of a drug from one scale to another or between manufacturing sites presents both technical and business challenges.

Manufacturing highly toxic compounds in a biopharmaceutical environment tests equipment and systems.

Demand is driving expansion and consolidation of formulation and clinical trial materials services.

At DCAT's annual meeting, Bill Downey, president of the market research firm High Tech Business Decisions, summarized results from its latest survey on biopharmaceutical outsourcing.

Collaboration will provide for unified development and manufacture of antibody drug conjugates.

Hovione will operate a commercial-scale continuous manufacturing facility in New Jersey as part of an agreement with Vertex Pharmaceuticals.

Global economic and political uncertainty could slow bio/pharma development activity.

The pharma outsourcing market starts 2016 with expansions, acquisitions, and new offerings.